In order to explore the association between NEDD8 mRNA expression and response to ICB therapy in breast cancer patients, we explored published RNA sequencing results from the I-SPY2 neoadjuvant platform trial (NCT01042379)16, where patients received paclitaxel or paclitaxel in combination with pembrolizumab. The gene discussed is NEDD8; the disease is breast carcinoma.